Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Lenalidomide delays progression of multiple myeloma after stem cell transplant

Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients.

14 May 2012

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

11 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

Everett Labs announces availability of Pregnitude for women with fertility problems

A new non-prescription Reproductive Support Dietary Supplement, Pregnitude, which contains myo-inositol (2 g), plus folic acid (200 mcg), is now available for women who are having difficulty conceiving, Everett Laboratories announced today. In clinical studies, Pregnitude has been shown to help support ovulation function and menstrual cycle regularity as well as support the quality of a woman's eggs.

8 May 2012

Research identifies molecular trigger of fibroid uterine tumors

Fibroid uterine tumors affect an estimated 15 million women in the United States, causing irregular bleeding, anemia, pain and infertility. Despite the high prevalence of the tumors, which occur in 60 percent of women by age 45, the molecular cause has been unknown.

5 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Ligand first quarter total revenues increase to $5.6 million

Ligand Pharmaceuticals Incorporated today reported financial results for the first quarter ended March 31, 2012, and provided an operating forecast and program updates.

3 May 2012

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

2 May 2012

Anlit Advanced Nutrition Supplements to present new products at Vitafoods Europe 2012

Anlit Advanced Nutrition Supplements, an innovative developer of quality consumer vitamins, minerals and dietary supplements for children, will present new and innovative products at Vitafoods Europe 2012, which will take place May 22-24, 2012 in Geneva, Switzerland.

2 May 2012

DaVita first quarter net income increases to $140.1 million

DaVita Inc. today announced results for the quarter ended March 31, 2012. Net income attributable to DaVita Inc. for the quarter ended March 31, 2012 was $140.1 million, or $1.46 per share.

2 May 2012

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

2 May 2012

AmerisourceBergen acquires World Courier Group

AmerisourceBergen Corporation today announced that it has completed the previously announced acquisition of World Courier Group, Inc., a privately held leading global specialty transportation and logistics provider for the biopharmaceutical industry.

2 May 2012

FANCM gene plays key role in recombination of genetic information during inheritance

Scientists of KIT and the University of Birmingham have identified relevant new functions of a gene that plays a crucial role in Fanconi anemia, a life-threatening disease. The FANCM gene is known to be important for the stability of the genome.

30 Apr 2012

UAB researcher wins HudsonAlpha Prize for work on sickle cell and related blood disorders

Tim Townes, Ph.D., University of Alabama at Birmingham, was awarded the HudsonAlpha Prize for his work on sickle cell and related blood disorders. The $20,000 monetary award acknowledges exceptional talent, dedication and discovery by Alabama's best and brightest researchers.

30 Apr 2012

Maternal stress during first trimester of pregnancy puts newborns at risk for iron deficiency

Newborns whose mothers are under stress during the first trimester of pregnancy may be at risk for low iron status, which could lead to physical and mental delays down the road, according to a study to be presented Sunday, April 29, at the Pediatric Academic Societies (PAS) annual meeting in Boston.

30 Apr 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

MSF says number of annual malaria cases treated in DRC has tripled since 2009

Ahead of World Malaria Day on April 25, Medecins Sans Frontieres (MSF) in the Democratic Republic of Congo (DRC) on Tuesday said the number of malaria cases it has treated in the country "more than tripled to 155,000 last year from two years previous," Reuters reports.

26 Apr 2012

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics, Inc., the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that it has filed for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for INFRADURE for the treatment of hepatitis D.

23 Apr 2012

EMA CHMP recommends approval of AMAG’s ferumoxytol

AMAG Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the approval of ferumoxytol, an intravenous (IV) iron therapy, for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

21 Apr 2012